new glp-1 drugs in development GLP Agonist Clinical Trial Pipeline Appears Robust With 20+ Emerging Weight Loss Drugs and

(28) GLP-1 Agonists and Surgical Outcomes Pre-Clinical Studies Liu et al

The symptoms persisted for a median duration of 47 days in people with obesity on GLP-1 RA therapy [18], which may be ascribed to the more chronic nature of the condition [35]

In real-world settings, efficacy may differ due to patients ability to remember to take the medication, administer it properly, tolerate its side effects, and more

Clinical trials have shown that Rybelsus lowers HbA1c significantly and supports weight loss, similar to injectable semaglutide

Since higher-dose formulations of oral and subcutaneous semaglutide are under development, it needs to be seen if they will be approved as anti-obesity drugs [34]